What ACI patients can realistically expect at ten years

For patients weighing up a procedure that demands a two-stage operation and months of rehabilitation, the core question is straightforward: does ACI still deliver a decade on? The current evidence suggests it does, and two 2024 studies provide the clearest picture yet.

A 10-year prospective cohort following 204 MACI patients (168 assessed clinically, 151 via MRI) found that 92% were satisfied with their pain relief at the ten-year mark, and 76% were satisfied with their ability to participate in sport. MRI assessment identified graft failure — defined as delamination — in 9.3% of grafts (14 of 151 reviewed); the remainder showed satisfactory tissue infill. A 2024 systematic review covering 168 patients across 188 chondral defects, with a mean patient age of 37 years and follow-up extending to 17 years, confirmed durable improvements across all patient-reported outcome measures throughout that period.

The surgical re-intervention picture is similarly reassuring. The all-cause reoperation rate was 9.0%, and 7.4% of patients progressed to total knee arthroplasty (TKA) over a 10–17-year window. These figures carry more weight when set against the natural history of untreated focal chondral defects, which are associated with progressive pain, functional decline, and a substantially higher risk of eventual joint replacement.

These are not figures to overstate. Graft failure and TKA conversion are real outcomes that affect a minority of patients, and a consultant assessment remains essential to determine whether ACI is appropriate for any individual. What the data do establish is that, for carefully selected patients, the benefits achieved in the first two years appear to hold.

Why improvement peaks in year two and then holds steady

The trajectory of recovery after MACI follows a consistent and clinically important pattern. Data from the ten-year prospective cohort confirm that all patient-reported outcome measures improved significantly within the first two years of surgery (P<.0001) — and then, from year two through year ten, no statistically significant change was recorded in any PRO or MRI-based MOCART variable.

That plateau deserves careful interpretation. It is not stagnation. It means the functional gains achieved in the early post-operative period are held, not eroded — for eight or more years. Structural MRI findings mirror the clinical picture: MOCART scores remained stable from year two onwards, confirming that the tissue repair is durable as well as symptomatic.

Setting realistic expectations around this pattern matters. Patients sometimes hope that scores will continue climbing year on year; the evidence says otherwise. The goal of MACI is sustained, meaningful function — not a trajectory of ongoing improvement. Most of the benefit is consolidated by the two-year mark, and the body of long-term data suggests it stays there.

Put plainly: significant gains in the first couple of years, then a stable plateau. For a procedure undertaken on a knee that would otherwise continue to deteriorate, that stability is the outcome.

Graft survival, reoperation, and conversion to joint replacement

Alongside the reassuring long-term figures already outlined, certain complications deserve honest acknowledgement. Published experience with scaffold-based cartilage repair identifies graft hypertrophy — where repair tissue overgrows the defect margin — together with arthrofibrosis, graft hypotrophy, and graft dislodgement as recognised postoperative events. None are frequent, and the literature consistently emphasises that early clinical and imaging review, followed by timely intervention, limits their long-term impact. These are real risks rather than predictable outcomes, and the distinction matters when counselling patients.

The procedural commitment that MACI and earlier-generation ACI demand is also worth setting out plainly. The first stage is an arthroscopic biopsy to harvest a small sample of healthy chondrocytes from a low-load area of the joint; those cells are then expanded in laboratory culture over several weeks before the second procedure — implantation — takes place. For most patients that interval is workable, but it represents a logistical and psychological investment that a single-session intervention does not carry. Emerging one-stage ACI variants aim to reduce that burden, though their long-term evidence base has not yet accumulated to the level of the established two-stage procedure.

These considerations — complication profile, staged surgery, and recovery demands — form part of the shared decision-making conversation a consultant will have with any patient who is a potential candidate.

How ACI and MACI compare to microfracture over a decade

Technique choice turns out to matter considerably — not just in the immediate post-operative period, but across the full decade of follow-up.

Microfracture has a well-documented pattern: early gains that do not hold. A 10-year RCT comparing AMIC® to microfracture (47 patients) found that the microfracture group deteriorated progressively and significantly after year two, whilst both AMIC® groups remained clinically stable at ten years. That finding aligns with the wider literature: microfracture stimulates fibrocartilage formation rather than hyaline-like repair tissue, and fibrocartilage tends to break down under load from around years two to three. Microfracture also carries a recognised risk of damaging the subchondral bone plate, which may compromise the success of any subsequent repair procedure — a practically important consideration for younger patients who may need further intervention.

The comparative score data from a five-year RCT of costal chondrocyte–derived pellet ACI versus microfracture are specific: MOCART 62.3 versus 26.7 (P<.0001), Lysholm 84.5 versus 64.9 (P=.023), and KOOS total 390.9 versus 303.0 (P=.017), with no treatment failures in the ACI group versus one in the microfracture arm.

In the short term — up to two years — MACI, AMIC, and arthroscopic minced cartilage implantation appear equivalent on patient-reported outcomes. Where the approaches diverge is in sustained durability: the ten-year evidence base currently favours matrix-assisted and cell-based techniques. For patients planning a procedure today, that distinction between what works initially and what holds over a decade is a central part of the decision.

Which patients face a higher risk of graft failure

Not all patients who are eligible for ACI face the same probability of graft success, and the evidence now identifies one combination of risk factors that warrants particular attention in pre-operative planning.

A case-control study of 38 ACI patients who had previously undergone a failed marrow stimulation procedure found an overall graft failure rate of 21% — more than double the approximately 9% observed in the broader MACI literature. The specific driver was severe preoperative subchondral bone marrow oedema: patients with grade IV oedema on MRI were significantly more likely to experience graft failure (P<.001). The clinical implication is direct: MRI grading of bone marrow oedema is not a formality but an integral part of responsible patient selection, and it should be completed and discussed before any implantation decision is confirmed.

Prior microfracture does not automatically disqualify a patient from ACI — consultants regularly treat patients in exactly that situation. What it does require is explicit, documented discussion of the elevated risk profile, and in some cases, additional attention to the condition of the subchondral bed before or during implantation. Donor variability in harvested chondrocyte quality and defect location are further individual-level factors that a consultant will weigh alongside the MRI findings.

The practical message is that thorough pre-operative assessment, with careful MRI evaluation at its centre, materially improves the shared decision-making conversation and may influence the timing or sequencing of intervention.

Where the evidence still has gaps

Confidence in the ten-year evidence base is warranted, but some important questions remain unanswered or only partially addressed by the current literature.

The most substantive limitation concerns which generation of ACI is actually being studied. The large 10-year cohorts and systematic reviews draw predominantly on first- and second-generation procedures — open surgery using a periosteal or collagen membrane patch. Third-generation techniques, which allow arthroscopic implantation via a scaffold (including MACI in its current form), and fourth-generation one-stage approaches have shorter published follow-up series. Whether the durable PRO plateau observed in older cohorts translates equally to these newer techniques is not yet established.

Biomechanical recovery presents a separate and subtler gap. Gait analysis after spheroid-based MACI found that patients who reported meaningful clinical improvement — IKDC rising from 56.6 to 73.1, satisfaction at 94.3% — still showed persistently reduced self-selected walking speed and peak knee flexion compared with healthy controls. Patient-reported recovery and objective biomechanical normalisation do not move in step, and the long-term implications of that discrepancy are not yet clear.

At a biological level, current ACI implants a heterogeneous chondrocyte mixture that does not recreate the layered zonal architecture of native articular cartilage. That structural mismatch may partly explain why mechanical performance can lag behind symptomatic improvement and why longer-term outcomes in higher-demand joints remain uncertain.

Two patient populations are particularly under-represented in the decade-long data: those with patellofemoral defects, where biomechanical stresses differ from the tibiofemoral compartment, and competitive athletes, for whom return-to-sport rates and durability under high load are the most clinically relevant endpoints but are not robustly reported beyond five years. For both groups, decisions currently rest on extrapolation from shorter follow-up series rather than direct long-term evidence.

1. [1] 10-Year Prospective Clinical and Radiological Evaluation After Matrix-Induced Autologous Chondrocyte Implantation and Comparison of Tibiofemoral and Patellofemoral Graft Outcomes. (2024). https://doi.org/10.1177/03635465241227969 https://doi.org/10.1177/03635465241227969
2. [2] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
3. [3] Metabolic modulation to improve MSC expansion and therapeutic potential for articular cartilage repair. (2024). https://doi.org/10.1186/s13287-024-03923-w https://doi.org/10.1186/s13287-024-03923-w
4. [4] Cartilage Repair with Autologous Chondrocytes (ACI Generations 1-4). (2024). https://doi.org/10.1016/j.csm.2024.08.003 https://doi.org/10.1016/j.csm.2024.08.003
5. [5] Autologous bone grafting combined with spheroid-based matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee. (2025). https://doi.org/10.1002/ksa.12605 https://doi.org/10.1002/ksa.12605
6. [6] Severe Bone Marrow Edema Among Patients Who Underwent Prior Marrow Stimulation Technique Is a Significant Predictor of Graft Failure After Autologous Chondrocyte Implantation. (2019). https://doi.org/10.1177/0363546519853584 https://doi.org/10.1177/0363546519853584
7. [7] Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation Versus Microfracture for the Treatment of Articular Cartilage Defects: A 5-Year Follow-up of a Prospective Randomized Trial. (2024). https://doi.org/10.1177/03635465231222797 https://doi.org/10.1177/03635465231222797
8. [8] A randomized controlled trial demonstrating sustained benefit of autologous matrix-induced chondrogenesis (AMIC®) over microfracture: 10-year follow-up. (2024). https://doi.org/10.1007/s00590-024-03948-0 https://doi.org/10.1007/s00590-024-03948-0
9. [9] Comparison of Three Different Techniques for the Treatment of Cartilage Lesions—MACI vs AMIC and Arthroscopic Minced Cartilage—A 2-Year Follow-Up. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194
10. [10] Improved Articular Cartilage Repair With Stratified Zonal Chondrocyte Implantation. (2025). https://doi.org/10.1177/03635465251343288 https://doi.org/10.1177/03635465251343288
11. [11] Biologic Augmented Scaffold-based cartilage repair: Addressing Complications and Enhancing Outcomes. (2025). https://doi.org/10.1016/j.jcot.2025.102905 https://doi.org/10.1016/j.jcot.2025.102905